You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 03/04/2015

Company Name Symbol %Change
LEMAITRE VAS LMAT
6.52%
EXFO INC EXFO
5.53%
AUTOBYTEL IN ABTL
4.99%
MARKETAXESS MKTX
4.39%
AKORN INC AKRX
3.77%

Tale of the Tape

PetSmart (PETM) Q4 Earnings & Revenue Beats Estimates

Posted Wed Mar 04, 10:24 am ET

by Zacks Equity Research

PetSmart, Inc. (PETM), specialty retailer of products, services, and solutions for pets, came out with fourth-quarter fiscal 2014 results, wherein adjusted earnings of $1.43 per share beat the Zacks Consensus Estimate of $1.37, and surged 11.7% from the prior-year quarter.

Including one-time items earnings came in at $1.32 per share, up 3.1% year over year.

Earnings Estimate Revision: The Zacks Consensus Estimate for fiscal 2014 and 2015 has been portraying an uptrend in the last 30 days. In the trailing four quarters (including the quarter under review), the company has outperformed the Zacks Consensus Estimate by an average of 4.5%.

Revenues: PetSmart generated total revenue of $1,913.8 million that increased 6% year over year, and also came ahead of the Zacks Consensus Estimate of $1,862 million. Consolidated comparable-store sales jumped 2.6%.

Key Events: Last December PetSmart entered into a deal to be acquired by a consortium led by BC Partners at $83.00 per share in cash. The transaction is expected to conclude in the first quarter of fiscal 2015.

Zacks Rank: Currently, PetSmart carries a Zacks Rank #2 (Buy) which is subject to change following the earnings announcement.

Check back later for our full write up on PetSmart’s earnings report!

Want the latest recommendations from Zacks Investment Research? Today, you can download

7 Best Stocks for the Next 30 Days. Click to get this free report >>

The Joint Corp. (JYNT) Worth a Look: Stock Rises 6.1%

Posted Wed Mar 04, 09:46 am ET

by Zacks Equity Research

The Joint Corp. (JYNT) was a big mover last session, as the company saw its shares rise over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 20.5% since Feb 20, 2015.

The company has seen no estimate revisions over the past 30 days, while the Zacks Consensus Estimate remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

The Joint Corp. currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
 
A better-ranked stock in the same industry is Magellan Health, Inc. (MGLN), which sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

 

PharMerica Corporation (PMC) Jumps: Stock Adds 5%

Posted Wed Mar 04, 09:32 am ET

by Zacks Equity Research

PharMerica Corporation (PMC) was a big mover last session, as the company saw its shares rise 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock is now up 15.39% since Feb 20.

None of the estimates for this stock were revised in the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

PharMerica carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.

A better-ranked stock in the drug stores industry is Almost Family Inc. (AFAM), sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Zacks Rank #5 Additions for Wednesday

Posted Wed Mar 04, 09:30 am ET

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Acacia Research Corp ( ACTG )
  • Allot Communications Ltd ( ALLT )
  • Amber Road Inc (AMBR )
  • American Vanguard Corp. (AVD)
  • Arch Coal Inc (ACI)

View the entire Zacks Rank #5 List.

 

Zacks Rank #1 Additions for Wednesday

Posted Wed Mar 04, 09:30 am ET

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

  • Altisource Residential Corporation (RESI)
  • American States Water Company (AWR)
  • Avago Technologies Limited (AVGO)
  • Axcelis Technologies Inc. (ACLS)
  • Berkshire Hathaway Inc. (BRK.B)

View the entire Zacks Rank #1 List.

 

Cytori Therapeutics (CYTX) Jumps: Stock Moves 7.1% Higher

Posted Wed Mar 04, 09:25 am ET

by Zacks Equity Research

Cytori Therapeutics, Inc. (CYTX) was a big mover last session with its shares rising over 7% on the day. The upside was owing to the company’s announcement that it will be presenting at the 35th Annual Cowen and Company Health Care Conference to be held in Boston from March 2-5, 2015. The company’s presentation is scheduled for today. This development led to far more shares changing hands yesterday than in a normal session. The move continues the recent uptrend of the company as the stock has gained a massive 150% in the past one-month time frame.

This cell therapy company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same period. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this stock in the near future.

Cytori Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the biomedical industry may consider Affymetrix Inc. (AFFX) which sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Abercrombie & Fitch (ANF) Q4 Earnings and Revenues Fall Y/Y

Posted Wed Mar 04, 09:23 am ET

by Zacks Equity Research

Abercrombie & Fitch Co. (ANF), a specialty retailer of premium, high-quality casual apparel, released fourth-quarter fiscal 2014 results, wherein adjusted earnings of $1.15 a share came ahead of the Zacks Consensus Estimate of $1.13. Moreover, the bottom line fell nearly 14.2% from $1.34 a share earned in the year-ago quarter.

 

Though the company has held back its earnings and comparable store sales guidance until it gets a clear picture of the impact of its ongoing strategic initiatives, it provided a sneak peek on factors that may impact fiscal 2015 performance. It expects foreign currency headwinds to significantly impact its fiscal 2015 results.  Further, it expects the negative impact of reduced logo sales to modestly subside in the first half of fiscal 2015 and neutralize in the second half, thus, benefiting the comparable store sales results.

 

Earnings Estimate Revision: The Zacks Consensus Estimate has been witnessing a downtrend in the last 60 days. However, Abercrombie & Fitch’s performance in fiscal 2014 remains encouraging. The company has posted positive earnings surprises of 5.6%, 90% and 2.4% in the first, second and third quarter of fiscal 2014, respectively. Moreover, the company delivered a positive earnings surprise of 1.8% in the quarter under review.

 

In the trailing four quarters, including the quarter under review, the company outperformed the Zacks Consensus Estimate by an average of 25%.

 

Revenues: Abercrombie & Fitch’s net sales dipped 14% year over year to $1,120 million and missed the Zacks Consensus Estimate of $1,174 million, primarily due to dismal comparable store sales performance, negative impact from foreign currency translations and net store closures. Comparable store sales slipped 10%.

 

Key Events: Abercrombie & Fitch declared a quarterly dividend of 20 cents per share, payable on Mar 11 to shareholders with record as on Mar 3.

 

Zacks Rank: Currently, Abercrombie & Fitch carries a Zacks Rank #5 (Strong Sell) which is subject to change following the earnings announcement.

 

Stock Movement: Abercrombie & Fitch’s shares are down nearly 5.5% during pre-market trading hours following the earnings release. Clearly, a negative sentiment is palpable among investors following the company’s financial results.

 

Check back later for our full write up on Abercrombie & Fitch’s earnings report!

 

Want the latest recommendations from Zacks Investment Research? Today, you can download

 

7 Best Stocks for the Next 30 Days. Click to get this free report >>

CEL-SCI Corporation (CVM) in Focus: Stock Jumps 5.6%

Posted Wed Mar 04, 09:21 am ET

by Zacks Equity Research

CEL-SCI Corporation (CVM) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 75.38% in the past one-month time frame.
 
None of the estimates for this biotechnology stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
 
CEL-SCI Corporation currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
 
A better-ranked stock in the same industry is Affymetrix Inc. (AFFX), sporting a Zacks Rank #1 (Strong Buy).
 
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Catalent, Inc. (CTLT) in Focus: Stock Jumps 5.4%

Posted Wed Mar 04, 09:18 am ET

by Zacks Equity Research

Catalent, Inc. (CTLT) was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend of the company, as the stock is now trading above the volatile price range of $27.34 to $29.60 in the past one-month time frame.
 
None of the estimates for this medical drugs stock were revised over the past seven days. The Zacks Consensus Estimate however moved higher over the same time frame, suggesting that more solid trading could be ahead for this stock. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
 
Catalent currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
 
A better-ranked stock in the same industry is Lannett Company, Inc. (LCI), sporting a Zacks Rank #1 (Strong Buy).
 
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Fibrocell Science (FCSC) in Focus: Stock Surges 11%

Posted Wed Mar 04, 09:11 am ET

by Zacks Equity Research

Fibrocell Science, Inc. (FCSC) was a big mover last session, as the company saw its shares rise almost 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 31.7% in the past one-month time frame.

The company has seen no estimate revisions in the past 30 days and the Zacks Consensus Estimate has also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
 
Fibrocell Science currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

A better-ranked stock in the same space is ANI Pharmaceuticals, Inc. (ANIP), sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Full Archive

The content contained in this weblog feature may have been abstracted from a complete Zacks Equity Research report.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.